SI1176960T1 - Synergistic combination comprising roflumilast and a pde-3 inhibitor - Google Patents

Synergistic combination comprising roflumilast and a pde-3 inhibitor

Info

Publication number
SI1176960T1
SI1176960T1 SI200030562T SI200030562T SI1176960T1 SI 1176960 T1 SI1176960 T1 SI 1176960T1 SI 200030562 T SI200030562 T SI 200030562T SI 200030562 T SI200030562 T SI 200030562T SI 1176960 T1 SI1176960 T1 SI 1176960T1
Authority
SI
Slovenia
Prior art keywords
pde
inhibitor
sub
roflumilast
synergistic combination
Prior art date
Application number
SI200030562T
Other languages
English (en)
Slovenian (sl)
Inventor
Hermann Amschler
Rolf Beume
Dietrich H�FNER
Christian Schudt
Armin Hatzelmann
Ulrich Kilian
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of SI1176960T1 publication Critical patent/SI1176960T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200030562T 1999-05-04 2000-04-27 Synergistic combination comprising roflumilast and a pde-3 inhibitor SI1176960T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99108808 1999-05-04
EP00927094A EP1176960B1 (en) 1999-05-04 2000-04-27 Synergistic combination comprising roflumilast and a pde-3 inhibitor
PCT/EP2000/003838 WO2000066123A1 (en) 1999-05-04 2000-04-27 Synergistic combination comprising roflumilast and a pde-3 inhibitor

Publications (1)

Publication Number Publication Date
SI1176960T1 true SI1176960T1 (en) 2005-04-30

Family

ID=8238107

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030562T SI1176960T1 (en) 1999-05-04 2000-04-27 Synergistic combination comprising roflumilast and a pde-3 inhibitor

Country Status (11)

Country Link
US (2) US6498173B1 (es)
EP (1) EP1176960B1 (es)
JP (1) JP2002543133A (es)
AT (1) ATE277616T1 (es)
AU (1) AU4558800A (es)
CA (1) CA2372850C (es)
DE (1) DE60014353T2 (es)
ES (1) ES2228512T3 (es)
PT (1) PT1176960E (es)
SI (1) SI1176960T1 (es)
WO (1) WO2000066123A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407780A1 (en) * 2000-05-25 2001-11-29 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
WO2002051502A1 (en) * 2000-12-22 2002-07-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
ME00524B (me) 2003-03-10 2011-10-10 Astrazeneca Ab Novi postupak za dobijanje roflumilasta
CA2601250C (en) 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
US20090209599A1 (en) * 2005-06-09 2009-08-20 Yoko Endo Eye drop containing roflumilast
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929208D0 (en) * 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
SI0706513T1 (en) * 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
EP0961616A4 (en) * 1996-09-13 2000-11-22 Trustees Of Board Of NON-HORMONAL CONTRACEPTIVE METHOD
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses

Also Published As

Publication number Publication date
US6897229B2 (en) 2005-05-24
EP1176960A1 (en) 2002-02-06
CA2372850C (en) 2011-01-18
PT1176960E (pt) 2005-02-28
WO2000066123A1 (en) 2000-11-09
US20030050329A1 (en) 2003-03-13
EP1176960B1 (en) 2004-09-29
ES2228512T3 (es) 2005-04-16
US6498173B1 (en) 2002-12-24
ATE277616T1 (de) 2004-10-15
DE60014353T2 (de) 2005-10-13
DE60014353D1 (de) 2004-11-04
JP2002543133A (ja) 2002-12-17
AU4558800A (en) 2000-11-17
CA2372850A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
SI1176960T1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
DK1202986T3 (da) Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
PL363316A1 (en) Substituted triazole diamine derivatives as kinase inhibitors
MXPA03003912A (es) Tratamientos nuevos para el sindrome de piernas inquietas.
PL359022A1 (en) Use of cyp2d6 inhibitors in combination therapies
MXPA03006260A (es) Derivados de amina sustituidos y metodos de uso.
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
PL365520A1 (en) Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
AU2001274598A1 (en) Antitumor effect potentiators
AU2002340010A1 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
HK1054194A1 (en) Stabilized aqueous suspensions for parenteral use
AU9411701A (en) Combination use of acetylcholinesterase inhibitors and gaba<sub>A</sub> inverse agonists for the treatment of cognitive disorders
IL158776A0 (en) A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
WO2002016312A3 (de) NEUE VERBINDUNGEN, DIE FAKTOR Xa-AKTIVITÄT INHIBIEREN
EP1337255A4 (en) USE OF P38 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY COUGH
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
MY119312A (en) At 1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
EP0356035A3 (en) Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
CA2364258A1 (en) 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect